Bavencio
Bavencio ingredients
| Active ingredient | Strength |
|---|---|
| Avelumab | 20 mg/mL |
What Bavencio is used for
The FDA lists the approved uses on the official label (below). In the EU, avelumab is approved as Bavencio for:
Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Bavencio
- Generic name
- Avelumab
- Made by
- EMD Serono, Inc.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- Programmed Death Ligand-1 Blocker
- FDA approval
- Biologic licence (BLA) BLA761049
- On the US market since
- 2017
Official information
- MedlinePlus drug information (search for Avelumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Bavencio?
Bavencio (Avelumab) is a cancer medicine made by EMD Serono, Inc., approved by the US FDA.
What are the ingredients of Bavencio?
Bavencio contains Avelumab (20 mg/mL).
Is Bavencio approved in Europe?
The same active substance is approved in the EU as Bavencio.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA